Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyA Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in CardiomyocytesTwenty years of anti-HER2 therapy-associated cardiotoxicityLapatinib in the treatment of breast cancerMitochondria-specific accumulation of amyloid β induces mitochondrial dysfunction leading to apoptotic cell deathCardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Cardiotoxicity of the anticancer therapeutic agent bortezomib.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.ErbB signaling in cardiac development and disease.Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarction.Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteinsAnti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failureNeuregulin-1β for the treatment of systolic heart failure.Breast cancer therapy and cardiovascular risk: focus on trastuzumabTrastuzumab-induced cardiac dysfunction: A 'dual-hit'Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathwaysActivation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.A novel clinical indicator using cardiac technetium-99m sestamibi kinetics for evaluating cardiotoxicity in cancer patients treated with multiagent chemotherapy.Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolismBidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.Cardiac side effects of anticancer treatments: new mechanistic insightsNeuregulin in cardiovascular development and diseasePalmitate alters neuregulin signaling and biology in cardiac myocytesTrastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?The role of Neuregulin-1beta/ErbB signaling in the heart.Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytesChronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cellsReduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice.HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure.Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins.Emerging role of neuregulin as a modulator of muscle metabolism.Cardiotoxicity.Cardiotoxicity associated with targeting kinase pathways in cancer.Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
P2860
Q21284978-E471CB88-CA37-497F-B67F-384494135BD9Q27667526-CCCEA837-A96B-4612-83B9-0E11F917BE66Q28079391-D91EF624-34BA-49CA-87A7-A6C124C51C6EQ28250382-26D4CC4F-90FE-4B9F-BF17-57FB510F587CQ28730589-1BA78793-7CBF-4235-9667-27EEA806837BQ33352155-1AA0C6E2-B408-46BB-9AC6-56CB573D59DDQ33595716-04429776-BD41-4602-8439-19FDEFE39A25Q33882390-D43476E8-AE72-4D75-9820-AB902EDFDB66Q34363419-34F73807-AF01-4679-934D-715E3B60CEC5Q34388932-85BAAA47-6A77-4F50-9BD8-27A0714BA4A8Q34545577-844737E1-8194-4987-A563-DC641AA28146Q34598168-7D7C4D9B-09EA-4CCD-A972-305D083BC1C2Q34993878-ED3DD5E7-2F1D-47E5-A8D2-B3363A84CF13Q35070764-B60A1F5E-8A99-447A-98E5-87ED113873BDQ35231868-76E7CA95-D0EB-49D5-B1C8-81D7600DC4DAQ35427876-0B79DC03-2529-4E2C-B052-0C05690A19E1Q35532125-1BC74ECE-8B59-4036-92D5-37E8EB397B03Q35605824-35651C03-59A6-4F39-9D10-F16DC2D1B1BCQ35973421-5970776D-DCE9-49FC-8D91-A5247EF781A8Q36339400-CC7FFDA3-8151-4609-B035-1A6397655A03Q36404564-DFEF01DA-04B1-494E-A722-1A2F17E5A23EQ36464712-079B4420-3F41-4F95-AC83-D02544DADE05Q36575695-EC90F7B5-08C3-4DBC-9B06-7648DB4AEFA9Q36957758-8CD1E881-C316-470A-AE52-E02C0C29AE44Q37118330-3D668110-2D4F-47E1-A70D-B1A34B59CFF5Q37124477-688AF73E-6D45-4A0B-BC54-E92C16A253FFQ37131070-570A7CB2-D04D-4F04-B36D-63466A1B22E9Q37155921-8E634D2A-30E1-4705-93BF-8DBF374127E6Q37189988-FF2A4C80-D0E7-4D9B-AF68-B67E5C23D2E4Q37195581-0572323A-E7A2-435E-A08D-6E447488E1A0Q37203741-E6A1F210-45B1-46B8-9804-3EAF01D9C8B6Q37260512-27A92C33-8FC4-4606-A416-92A7D0EB710EQ37264435-6736BE5D-5EFB-4AFE-91C5-22E9C6429DA7Q37380727-18DC9723-4414-4DA5-8A16-DA506AEEA649Q37435637-D9578573-EF36-4263-895F-218A58356FEDQ37474816-BE13D4E4-183E-4B32-A46B-BE90BF3BCF8DQ37661237-F914BA02-08A9-453F-B190-EB2562366AD5Q37799924-95F3EC30-E801-4168-9CDD-0EEB607A7A24Q37823035-793F72EB-62DB-4316-BA3D-BC4D46116B54Q37999108-90A23572-28D3-4AB6-8E7A-14D631BE735A
P2860
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Inhibition of ErbB2 causes mit ...... ceptin-induced cardiomyopathy.
@en
Inhibition of ErbB2 causes mit ...... ceptin-induced cardiomyopathy.
@nl
type
label
Inhibition of ErbB2 causes mit ...... ceptin-induced cardiomyopathy.
@en
Inhibition of ErbB2 causes mit ...... ceptin-induced cardiomyopathy.
@nl
prefLabel
Inhibition of ErbB2 causes mit ...... ceptin-induced cardiomyopathy.
@en
Inhibition of ErbB2 causes mit ...... ceptin-induced cardiomyopathy.
@nl
P2093
P1476
Inhibition of ErbB2 causes mit ...... ceptin-induced cardiomyopathy.
@en
P2093
Anthony Rosenzweig
Luanda P Grazette
Marc Semigran
Roger J Hajjar
Takashi Matsui
Wolfgang Boecker
P304
P356
10.1016/J.JACC.2004.08.066
P407
P50
P577
2004-12-01T00:00:00Z